Fesoterodine
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Toviaz |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609021 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | G04BD11 (WHO) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 52% (active metabolite) |
| Protein binding | 50% (active metabolite) |
| Metabolism | Hepatic (CYP2D6- and 3A4-mediated) |
| Biological half-life | 7–8 hours (active metabolite) |
| Excretion | Renal (70%) and fecal (7%) |
| Identifiers | |
| |
| CAS Number |
286930-02-7  |
| PubChem (CID) | 6918558 |
| IUPHAR/BPS | 7473 |
| DrugBank |
DB06702  |
| ChemSpider |
5293755 |
| UNII |
621G617227 |
| KEGG |
D07226 |
| ChEMBL |
CHEMBL1201764 |
| ECHA InfoCard | 100.167.339 |
| Chemical and physical data | |
| Formula | C26H37NO3 |
| Molar mass | 411.278 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]
Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.
Efficacy
Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.[5] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.[5]
References
- ↑ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006.
- ↑ "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008.
- ↑ "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Retrieved 2008-11-06.
- ↑ Notice of Decision for TOVIAZ
- 1 2 Vella, M.; Cardozo, L. (2011). "Review of fesoterodine". Expert Opinion on Drug Safety. 10 (5): 805–808. doi:10.1517/14740338.2011.591377. PMID 21639817.